Clariane Stock: +2.14% at Close, but -5.39% Over the Week
Clariane's stock rebounds at Wednesday's close, gaining 2.14% to EUR 4.004 after its previous day's plummet. This recovery occurs in a generally weak market, with the CAC 40 down by 0.19%. However, the stock still shows a significant decline over seven days, weakened by the downward revision of its profitability targets announced on Tuesday. This collapse marked the market's reaction to the company's results and warnings about its 2025 fiscal year.
Market Performance and Recent Trends
Clariane recorded a 2.14% gain this Wednesday, reaching EUR 4.004 after a 12.77% drop the previous day, where it fell to EUR 3.92. However, market activity remains low, with only 0.34% of the capital traded, indicating caution among participants despite the price rebound. Over a week, the stock has declined by 5.39%, reflecting the detrimental impact of the bad news earlier in the week. Over three months, the decline has intensified to 20.87%, although over a year, Clariane remains largely profitable with an increase of 88.87%. This annual performance strongly contrasts with that of the CAC 40, which only shows a +8.52% over the same period. This initial outperformance reflected the dynamics of the dependent care services sector before its recent correction. The Paris index, on the other hand, shows a slight decrease this Wednesday of 0.19%, remaining stable around 8,200 points.
Financial Trajectory and Recent Adjustments
The correction affecting Clariane since Tuesday results from the publication of mixed results and a cautious revision of its financial trajectory. In the third quarter, the group achieved a revenue of EUR 1.32 billion, growing by 5.1% organically, but this performance was below market expectations, which were set at EUR 1.38 billion. More concerning, Clariane has lowered its EBITDA forecasts for 2025, abandoning its initial range of +6% to +9% in favor of a less favorable scenario. The group cites delays in its cost-saving plans in France and Germany, as well as a slower-than-expected operational transformation. Some positive developments persist: the occupancy rate of nursing homes has increased to 90.8%, and Clariane has highlighted steady progress in its outpatient activities. However, these elements have not been sufficient to alleviate market concerns, particularly regarding the group's ability to restore its profitability.
Technical Analysis of the Stock
Technically, the stock shows marked fragility. The Relative Strength Index stands at 34, signaling conditions close to overselling. The MACD presents a bearish divergent configuration, while the stochastic oscillator confirms this degraded context. The price is trading below its 50-day moving average, established at EUR 4.37, while its 200-day moving average is at EUR 4.07. The gap between these two averages has narrowed to 0.30, reflecting a convergence of trends. Bollinger Bands position the stock in its lower band, with volatility remaining high at 16.76% over a month. The major support remains positioned at EUR 3.92, while the nearest resistance is at EUR 4.74.
